For 150 years, Boston Children’s has embodied a culture of scientific investigation that has shaped pediatric medicine and changed children’s lives. This legacy continues today as we lead the world in pediatric research, empowering clinicians and scientists to challenge the status quo and seek better answers for our patients.
Our research enterprise is the world's largest and most highly-funded pediatric hospital. In FY2018, we received more funding from the National Institutes of Health than any other children’s hospital in the nation. We perform research in a vast range of specialties, revolutionizing treatments for children with common conditions, such as asthma, diabetes and obesity, to children with rare and complex disorders.
Boston Children's leads or participates in hundreds of clinical trials. Use this database to find out which trials are recruiting, who can enroll and more.
A central hub of resources to support the Boston Children’s research community through guidance on planning, designing, implementing and reporting.
Three adult patients with sickle cell disease (SCD) are doing well after receiving an infusion of their own stem cells that had been genetically engineered to induce them to stop producing harmful “sickle” hemoglobin and start producing a healthy form of hemoglobin.
A drug used for rheumatoid arthritis has moved a step closer to FDA approval for a desperately needed new use. The drug, abatacept, has gained FDA Breakthrough Therapy Designation for preventing acute, severe graft-versus-host disease (GvHD) in patients receiving bone marrow transplants.
© 2005-2020 All Rights Reserved
